Literature DB >> 20974671

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.

Eva Martinez-Garcia1, Relja Popovic, Dong-Joon Min, Steve M M Sweet, Paul M Thomas, Leonid Zamdborg, Aaron Heffner, Christine Will, Laurence Lamy, Louis M Staudt, David L Levens, Neil L Kelleher, Jonathan D Licht.   

Abstract

The multiple myeloma SET domain (MMSET) protein is overexpressed in multiple myeloma (MM) patients with the translocation t(4;14). Although studies have shown the involvement of MMSET/Wolf-Hirschhorn syndrome candidate 1 in development, its mode of action in the pathogenesis of MM is largely unknown. We found that MMSET is a major regulator of chromatin structure and transcription in t(4;14) MM cells. High levels of MMSET correlate with an increase in lysine 36 methylation of histone H3 and a decrease in lysine 27 methylation across the genome, leading to a more open structural state of the chromatin. Loss of MMSET expression alters adhesion properties, suppresses growth, and induces apoptosis in MM cells. Consequently, genes affected by high levels of MMSET are implicated in the p53 pathway, cell cycle regulation, and integrin signaling. Regulation of many of these genes required functional histone methyl-transferase activity of MMSET. These results implicate MMSET as a major epigenetic regulator in t(4;14)+ MM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974671      PMCID: PMC3037745          DOI: 10.1182/blood-2010-07-298349

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.

Authors:  Gerben Duns; Eva van den Berg; Inge van Duivenbode; Jan Osinga; Harry Hollema; Robert M W Hofstra; Klaas Kok
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

Review 2.  Molecular pathogenesis and a consequent classification of multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl
Journal:  J Clin Oncol       Date:  2005-09-10       Impact factor: 44.544

3.  Genomic maps and comparative analysis of histone modifications in human and mouse.

Authors:  Bradley E Bernstein; Michael Kamal; Kerstin Lindblad-Toh; Stefan Bekiranov; Dione K Bailey; Dana J Huebert; Scott McMahon; Elinor K Karlsson; Edward J Kulbokas; Thomas R Gingeras; Stuart L Schreiber; Eric S Lander
Journal:  Cell       Date:  2005-01-28       Impact factor: 41.582

4.  Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species.

Authors:  Sawako Suzuki; Tomoaki Tanaka; Masha V Poyurovsky; Hidekazu Nagano; Takafumi Mayama; Shuichi Ohkubo; Maria Lokshin; Hiroyuki Hosokawa; Toshinori Nakayama; Yutaka Suzuki; Sumio Sugano; Eiichi Sato; Toshitaka Nagao; Koutaro Yokote; Ichiro Tatsuno; Carol Prives
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

5.  Deregulation of H3K27 methylation in cancer.

Authors:  Eva Martinez-Garcia; Jonathan D Licht
Journal:  Nat Genet       Date:  2010-02       Impact factor: 38.330

6.  A loss-of-function RNA interference screen for molecular targets in cancer.

Authors:  Vu N Ngo; R Eric Davis; Laurence Lamy; Xin Yu; Hong Zhao; Georg Lenz; Lloyd T Lam; Sandeep Dave; Liming Yang; John Powell; Louis M Staudt
Journal:  Nature       Date:  2006-03-29       Impact factor: 49.962

7.  Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

Authors:  Jonathan J Keats; Christopher A Maxwell; Brian J Taylor; Michael J Hendzel; Marta Chesi; P Leif Bergsagel; Loree M Larratt; Michael J Mant; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

8.  Serine 31 phosphorylation of histone variant H3.3 is specific to regions bordering centromeres in metaphase chromosomes.

Authors:  Sandra B Hake; Benjamin A Garcia; Monika Kauer; Stephen P Baker; Jeffrey Shabanowitz; Donald F Hunt; C David Allis
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-25       Impact factor: 11.205

9.  CpG islands recruit a histone H3 lysine 36 demethylase.

Authors:  Neil P Blackledge; Jin C Zhou; Michael Y Tolstorukov; Anca M Farcas; Peter J Park; Robert J Klose
Journal:  Mol Cell       Date:  2010-04-23       Impact factor: 17.970

10.  Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

Authors:  Ryan D Morin; Nathalie A Johnson; Tesa M Severson; Andrew J Mungall; Jianghong An; Rodrigo Goya; Jessica E Paul; Merrill Boyle; Bruce W Woolcock; Florian Kuchenbauer; Damian Yap; R Keith Humphries; Obi L Griffith; Sohrab Shah; Henry Zhu; Michelle Kimbara; Pavel Shashkin; Jean F Charlot; Marianna Tcherpakov; Richard Corbett; Angela Tam; Richard Varhol; Duane Smailus; Michelle Moksa; Yongjun Zhao; Allen Delaney; Hong Qian; Inanc Birol; Jacqueline Schein; Richard Moore; Robert Holt; Doug E Horsman; Joseph M Connors; Steven Jones; Samuel Aparicio; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nat Genet       Date:  2010-01-17       Impact factor: 38.330

View more
  168 in total

Review 1.  Many multiple myelomas: making more of the molecular mayhem.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Understanding the language of Lys36 methylation at histone H3.

Authors:  Eric J Wagner; Phillip B Carpenter
Journal:  Nat Rev Mol Cell Biol       Date:  2012-01-23       Impact factor: 94.444

3.  Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.

Authors:  Ping Yang; Linlang Guo; Zhijian J Duan; Clifford G Tepper; Ling Xue; Xinbin Chen; Hsing-Jien Kung; Allen C Gao; June X Zou; Hong-Wu Chen
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

Review 4.  Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus.

Authors:  Catalina Méndez; Chantelle L Ahlenstiel; Anthony D Kelleher
Journal:  World J Virol       Date:  2015-08-12

5.  Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape.

Authors:  Behnam Nabet; Pilib Ó Broin; Jaime M Reyes; Kevin Shieh; Charles Y Lin; Christine M Will; Relja Popovic; Teresa Ezponda; James E Bradner; Aaron A Golden; Jonathan D Licht
Journal:  Cell Rep       Date:  2015-08-13       Impact factor: 9.423

Review 6.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

7.  Proteomic approaches for cancer epigenetics research.

Authors:  Dylan M Marchione; Benjamin A Garcia; John Wojcik
Journal:  Expert Rev Proteomics       Date:  2018-11-27       Impact factor: 3.940

8.  Discovery platform for inhibitors of IgH gene enhancer activity.

Authors:  Nathan G Dolloff
Journal:  Cancer Biol Ther       Date:  2018-11-27       Impact factor: 4.742

9.  Overexpression of MMSET is correlation with poor prognosis in hepatocellular carcinoma.

Authors:  Peng Zhou; Lie-Lin Wu; Ke-Min Wu; Wei Jiang; Jin-Dong Li; Le-du Zhou; Xin-Ying Li; Shi Chang; Yun Huang; Hui Tan; Ge-Wen Zhang; Feng He; Zhi-Ming Wang
Journal:  Pathol Oncol Res       Date:  2012-12-08       Impact factor: 3.201

Review 10.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.